Pre-emptive Analgesia Using Nebulized Ketamine Versus Nebulized Dexmedetomidine in Endoscopic Nasal Surgeries

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

105 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-14

Study Completion Date

2025-10-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

this study aims to compare the efficacy of pre-emptive nebulized ketamine versus nebulized dexmedetomidine for post operative pain relief in endoscopic nasal surgery

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dexmedetomidine Versus Dexmedetomidine and Ketamine (Ketodex) in Ear and Nose Surgeries

NCT06981494

Ear and Nose Surgeries With Hypotensive Anaesthesia e.g FESS , MLS , TURBINECTOMY

RECRUITING NA

The Effect of Intraoperative Infusion of Dexmedetomidine Versus Low Dose Ketamine

NCT05828199

Nasal Polyps Nasal Septum, Irregular Functional Endoscopic Sinus Surgery

UNKNOWN PHASE1

Dexmedetomidine Versus Ketamine on Laryngeal Microsurgery

NCT07048873

Microlaryngeal Surgery

COMPLETED NA

Regional Nasal Block and Dexmedetomidine in Endoscopic Sinus Surgery

NCT05361642

Drug Use

UNKNOWN NA

Lidocaine and Dexmedetomidine Infusions for Intraoperative Bleeding in Functional Endoscopic Sinus Surgery

NCT06848764

Lidocaine Dexmedetomidine Infusion +2 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nose Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group D : will receive dexmedetomidine

Patients will receive nebulized dexmedetomidine 50 μg (0.5 ml +normal saline 0.9% up to 3 ml) 15 minutes prior to the onset of surgery.

Group Type ACTIVE_COMPARATOR

Dexmedetomidine

Intervention Type DRUG

patients in this group will receive nebulized Dexmedetomidine before onset of surgery

group K : will receive ketamine

patients will receive nebulized ketamine 50 mg (1 ml + normal saline 0.9%up to 3 ml) 15 minutes prior to the onset of surgery.

Group Type ACTIVE_COMPARATOR

Ketamine

Intervention Type DRUG

patients in this group will receive nebulized ketamine before onset of surgery

group C: will receive .9% saline

Patients will receive nebulized normal saline 0.9% (3 ml) 15 minutes prior to the onset of surgery.

Group Type PLACEBO_COMPARATOR

0.9%sodium chloride

Intervention Type DRUG

patients in this group will receive nebulized 0.9% normal saline before onset of surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexmedetomidine

patients in this group will receive nebulized Dexmedetomidine before onset of surgery

Intervention Type DRUG

Ketamine

patients in this group will receive nebulized ketamine before onset of surgery

Intervention Type DRUG

0.9%sodium chloride

patients in this group will receive nebulized 0.9% normal saline before onset of surgery

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients between the ages of 20 and 60,
* both sexes,
* American Society of Anesthesiologists physical status I to II
* BMI ≥18≤30 kg/m²

Exclusion Criteria

* Patient refusal.
* patients with advanced respiratory, renal, hepatic, neurological, or psychiatric disease, pregnant or nursing women.
* patients with a history of allergies to any study drugs.
* patients who had used central nervous system depressants or analgesics within the previous 24 hours.
* patients with hypertension, hypotension, or bradycardia.

Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No